cis-1-(4-Isopropyl-cyclohexyl)-piperidine-4-on | 1040363-80-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: cis-1-(4-Isopropyl-cyclohexyl)-piperidine-4-on
• 英文别名: cis-1-(4-isopropyl-cyclohexyl)-piperidin-4-one；1-(4-propan-2-ylcyclohexyl)piperidin-4-one
• CAS: 1040363-80-1
• 化学式: C₁₄H₂₅NO
• 分子量: 223.359
• InChiKey: FFRMQGVGWFANKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cis-1-(4-Isopropyl-cyclohexyl)-piperidine-4-on 在 silica gel 吡啶 作用下， 以 正戊烷 为溶剂， 生成 cis-[1-(4-isopropyl-cyclohexyl)-piperidin-4-ylidene]phenyl-amine
  参考文献：
  名称：

  Diaza-spiro[3,5] nonane derivatives

  摘要：

  该发明涉及一般式##STR1##的化合物，其中R.sup.1是C.sub.6-12-环烷基，可以选择性地被较低的烷基或C(O)O较低的烷基取代，或者是indan-1-yl或indan-2-yl，可以选择性地被较低的烷基取代；acenaphthen-1-yl；bicyclo[3.3.1]non-9-yl；八氢基-茚-2-yl；2,3-二氢-1H-苯莰-1-yl；2,3,3a,4,5,6-六氢-1H-苯莰-1-yl；十氢基-茚-2-yl；bicyclo[6.2.0]庚-9-yl；十氢基-萘-1-yl；十氢基-萘-2-yl；四氢基-萘-1-yl；四氢基-萘-2-yl或2-氧代-1,2-二苯基-乙基；R.sup.2是.dbd.O或氢，R.sup.3是氢，异吲哚基-1,3-二酮，较低的烷氧基，较低的烷基，氨基，苄氧基，--CH.sub.2OR.sup.5或--CH.sub.2N(R.sup.5).sub.2；R.sup.4是氢或--CH.sub.2OR.sup.5；R.sup.5是氢或较低的烷基；##STR2##是环己基或苯基，可以选择性地被较低的烷基，卤素或烷氧基取代；对于该发明的化合物的外消旋混合物及其相应的对映体和/或药学上可接受的酸盐。本发明的化合物是orphamin FQ（OFQ）受体的激动剂，因此在与该受体相关的疾病的治疗中非常有用。

  公开号：

  US06113527A1

文献信息

• Spiro[piperidine-4,1'-pyrrolo [3,4-C] pyrrole]derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06075034A1

  公开（公告）日：2000-06-13

  The present invention relates to compounds of the general formula wherein R.sup.1 is C.sub.5-12 -cycloalkyl, optionally substituted by lower alkyl; decahydro-naphthalen-1-yl; decahydro-naphthalen-2-yl; indan-1-yl or indan-2-yl, optionally substituted by lower alkyl; decahydro-azulen-2-yl; bicyclo[6.2.0]dec-9-yl; acenaphthen-1-yl; bicyclo[3.3.1]non-9-yl; 2,3-dihydro-1H-phenalen-1-yl; 2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl; octahydro-inden-2-yl; 1,2,3,4-tetrahydro-naphthalen-1-yl; 1,2,3,4-tetrahydro-naphthalen-2-yl; naphthalen-lower alkyl-1-yl; naphthalen-lower alkyl-2-yl; acenaphthen-1-yl; and 5-isopropyl-2-methyl-bicyclo[3.1.0]hex-3-yl; R.sup.2, R.sup.3 are hydrogen; hydroxy; lower alkyl; .dbd.O; or phenyl, optionally substituted by lower allyl, halogen or alkoxy; R.sup.4 is hydrogen; lower alkyl; --(CH.sub.2).sub.n CH(OH)CF.sub.3 ; --(CH.sub.2).sub.n C.sub.3-6 -cycloalkyl; phenyl; benzyl; tetrahydrofuran-3-yl; --(CH.sub.2).sub.n OCH.sub.2 C.sub.6 H.sub.5 ; --(CH.sub.2).sub.n morpholinyl; 3-methyl-oxetan-3-yl-methyl; --(CH.sub.2).sub.n CH.sub.2 OH; --S(O).sub.2 -lower alkyl; --C(O)-lower alkyl; --C(O)CF.sub.3 ; --C(O)(CH.sub.2).sub.n OCH.sub.3 ; --(CH.sub.2).sub.n C(O)N(lower alkyl).sub.2 ; --S(O).sub.2 heteroaryl; --C(O)heteroaryl; --S(O).sub.2 -phenyl; --S(O).sub.2 --N(lower alkyl).sub.2 ; --C(O)--C.sub.3-6 -cycloalkyl; --C(O)O-phenyl; or --C(O)O-lower alkyl: R.sup.5 is hydrogen; halogen; lower alkyl; trifluoromethyl or lower alkoxy; n is 0-3; and to pharmaceutically acceptable acid addition salts thereof The compounds of formula I and their salts are useful as in the treatment of psychiatric, neurological and physiological disorders.

  本发明涉及一般式化合物，其中R.sup.1是C.sub.5-12-环烷基，可以被较低的烷基取代；十氢萘-1-基；十氢萘-2-基；吲哚-1-基或吲哚-2-基，可以被较低的烷基取代；十氢萜烯-2-基；双环[6.2.0]癸-9-基；乙基萘-1-基；双环[3.3.1]壬-9-基；2,3-二氢-1H-苯并-1-基；2,3,3a,4,5,6-六氢-1H-苯并-1-基；八氢-茚-2-基；1,2,3,4-四氢萘-1-基；1,2,3,4-四氢萘-2-基；萘-较低烷基-1-基；萘-较低烷基-2-基；乙基萘-1-基；和5-异丙基-2-甲基-双环[3.1.0]己-3-基；R.sup.2、R.sup.3是氢；羟基；较低的烷基；.dbd.O；或苯基，可以被较低的烷基、烯丙基、卤素或烷氧基取代；R.sup.4是氢；较低的烷基；--（CH.sub.2).sub.n CH(OH)CF.sub.3；--（CH.sub.2).sub.n C.sub.3-6-环烷基；苯基；苄基；四氢呋喃-3-基；--（CH.sub.2).sub.n OCH.sub.2 C.sub.6 H.sub.5；--（CH.sub.2).sub.n 噻吩基；3-甲基-噁二烷-3-基-甲基；--（CH.sub.2).sub.n CH.sub.2 OH；--S（O）.sub.2-较低的烷基；--C（O）-较低的烷基；--C（O）CF.sub.3；--C（O）（CH.sub.2).sub.n OCH.sub.3；--（CH.sub.2).sub.n C（O）N（较低的烷基）.sub.2；--S（O）.sub.2杂环芳基；--C（O）杂环芳基；--S（O）.sub.2-苯基；--S（O）.sub.2--N（较低的烷基）.sub.2；--C（O）--C.sub.3-6-环烷基；--C（O）O-苯基；或--C（O）O-较低的烷基：R.sup.5是氢；卤素；较低的烷基；三氟甲基或较低的烷氧基；n为0-3；以及其药学上可接受的酸盐。式I化合物及其盐在精神病、神经病和生理疾病的治疗中有用。
• DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES
  申请人：——

  公开号：US20030176701A1

  公开（公告）日：2003-09-18

  The present invention relates to compounds of the general formula 1 wherein R 1 is C 6-10 -cycloalkyl, optionally substituted by lower alkyl or —C(O)O-lower alkyl; decahydro-naphthalen-1-yl; decahydro-naphthalen-2-yl; indan-1-yl or indan-2-yl, optionally substituted by lower alkyl; decahydro-azulen-2-yl; bicyclo[6.2.0]dec-9-yl; acenaphthen-1-yl; 2,3-dihydro-1H-phenalen-1-yl; 2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl or octahydro-inden-2-yl; R 2 is hydrogen; lower alkyl; ═O or phenyl, optionally substituted by lower alkyl, halogen or alkoxy; 2 is cyclohexyl or phenyl, optionally substituted by lower alkyl, halogen or alkoxy; X is —CH(OH)—; —C(O)—; —CHR 3 —; —CR 3 ═; —O—; —S—; —CH(COOR 4 )— or —C(COOR 4 )═; Y is —CH 2 —; —CH═; —CH(COOR 4 )—, —C(COOR 4 )═; or —C(CN)—; R 3 is hydrogen or lower alkoxy; R 4 is lower alkyl, cycloalkyl, phenyl, or benzyl and either a or b is optionally an additional bond, and to pharmaceutically acceptable acid addition salts thereof. The compounds are agonists of the orphanin FQ (QFQ) receptor and therefore useful in the treatment of diseases, related to this receptor.

  本发明涉及一般式1的化合物， 其中， R1是C6-10环烷基，可选地被较低烷基或-C（O）O-较低烷基取代； 十氢萘-1-基；十氢萘-2-基；吲哚-1-基或吲哚-2-基，可选地被较低烷基取代； 十氢-萜烯-2-基； 双环[6.2.0]癸-9-基； 萘并环[1]苯-1-基； 2,3-二氢-1H-菲-1-基； 2,3,3a,4,5,6-六氢-1H-菲-1-基或八氢-茚-2-基； R2是氢；较低烷基；═O或苯基，可选地被较低烷基，卤素或烷氧基取代； 2是环己基或苯基，可选地被较低烷基，卤素或烷氧基取代； X是—CH（OH）—；—C（O）—；—CHR3—；—CR3═；—O—；—S—；—CH（COOR4）—或—C（COOR4）═； Y是—CH2—；—CH═；—CH（COOR4）—，—C（COOR4）═；或—C（CN）—； R3是氢或较低烷氧基； R4是较低烷基，环烷基，苯基或苯甲基； a或b是可选的额外键，以及其药学上可接受的酸盐。 这些化合物是孤儿受体FQ（QFQ）激动剂，因此在与该受体相关的疾病的治疗中有用。
• HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF
  申请人：Brown Kevin C.

  公开号：US20100022519A1

  公开（公告）日：2010-01-28

  The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Heterocyclic-Substituted Piperidine Compound.

  本发明涉及杂环取代哌啶化合物，包括含有有效量的杂环取代哌啶化合物的组合物和治疗或预防疾病的方法，例如疼痛，通过向需要治疗的动物施用有效量的杂环取代哌啶化合物。
• Spiro(piperidine-4,1'-pyrrolo(3,4-c)pyrrole)
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0963987A2

  公开（公告）日：1999-12-15

  The present invention relates to compounds of the general formula    wherein the substituents are described in the application and to pharmaceutically acceptable acid addition salts thereof. The compound of the invention are useful in the treatment of diseases related to the orphanin FQ (OFQ) receptor, which include psychiatric, neurological and physiological disorders, such as anxiety and stress disorders, depression, trauma, memory loss due to Alzheimer's disease or other dementias, deficits in cognition and leaning, epilepsy and convulsions, acute and/or chronic pain conditions, and symptoms of addictive drug withdrawal, control of water balance, Na+ excretion, arterial blood pressure disorders and metabolic disorders such as obesity.

  本发明涉及通式为 其中的取代基见本申请所述，以及其药学上可接受的酸加成盐。 本发明的化合物可用于治疗与孤儿素 FQ（OFQ）受体有关的疾病，这些疾病包括精神、神经和生理疾病，如焦虑和应激障碍、抑郁症、创伤、阿尔茨海默病或其他痴呆症导致的记忆丧失、认知和精益功能障碍、癫痫和抽搐、急性和/或慢性疼痛病症、成瘾性药物戒断症状、水平衡控制、Na+排泄、动脉血压紊乱和代谢紊乱，如肥胖。
• Di-or triaza-spiro(4,5)decane derivatives
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0963985A2

  公开（公告）日：1999-12-15

  The present invention relates to compounds of the general formula wherein R1is C6-10-cycloalkyl, optionally substituted by lower alkyl or -C(O)O-lower alkyl; decahydro-naphthalen-1-yl; decahydro-naphthalen-2-yl; indan-1-yl or indan-2-yl, optionally substituted by lower alkyl; decahydro-azulen-2-yl; bicyclo[6.2.0]dec-9-yl; acenaphthen-1-yl; 2,3-dihydro-1H-phenalen-1-yl; 2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl or octahydro-inden-2-yl; R2is hydrogen; lower alkyl; =O or phenyl, optionally substituted by lower alkyl, halogen or alkoxy; Ⓐis cyclohexyl or phenyl, optionally substituted by lower alkyl, halogen or alkoxy; Xis -CH(OH)-; -C(O)-; -CHR3-; -CR3=; -O-; -S-; -CH(COOR4)- or - C(COOR4)=; Yis -CH2-; -CH=; -CH(COOR4)-, -C(COOR4)=; or -C(CN)-; R3is hydrogen or lower alkoxy; R4is lower alkyl, cycloalkyl, phenyl, or benzyl and either a or b is optionally an additional bond, and to pharmaceutically acceptable acid addition salts thereof. The compounds are agonists and/or antagonists of the orphanin FQ (QFQ) receptor and therefore useful in the treatment of diseases, related to this receptor.

  本发明涉及通式如下的化合物 式中 R1为C6-10-环烷基，任选被低级烷基或-C(O)O-低级烷基取代；十氢萘-1-基；十氢萘-2-基；茚-1-基或茚-2-基，任选被低级烷基取代；十氢氮杂环烯-2-基；双环[6.2.0]癸-9-基；苊-1-基；2,3-二氢-1H-苯戊烯-1-基；2,3,3a,4,5,6-六氢-1H-苯戊烯-1-基或八氢-茚-2-基； R2是氢；低级烷基；=O或苯基，可选择被低级烷基、卤素或烷氧基取代； 是环己基或苯基，可选择被低级烷基、卤素或烷氧基取代； X是-CH(OH)-；-C(O)-；-CHR3-；-CR3=；-O-；-S-；-CH(COOR4)-或-C(COOR4)=； Y是-CH2-；-CH=；-CH(COOR4)-，-C(COOR4)=；或-C(CN)-； R3 是氢或低级烷氧基； R4 是低级烷基、环烷基、苯基或苄基 和 a 或 b 是可选的附加键、 及其药学上可接受的酸加成盐。 这些化合物是孤儿素 FQ（QFQ）受体的激动剂和/或拮抗剂，因此可用于治疗与该受体有关的疾病。